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Abstract
Chemerin is a novel protein linked to adipocyte differentiation and the development of metabolic imbalances. We sought to
examine the relationship of chemerin with metabolic syndrome disturbances including body fat percentage, serum lipid,
glucose, insulin levels and body fat percentage in lean and obese volunteers. A cross-sectional study of 90 randomly
selected healthy males from Pakistan were divided into three groups as per Body Mass Index (BMI) criteria for South Asian
Population. Anthropometric measurements were taken for BMI, waist circumference, hip circumference and body fat
percentage, while serum analyses were performed for fasting blood glucose, fasting insulin, fasting lipid profile and serum
chemerin. Associations between serum chemerin levels and body fat and other metabolic syndrome parameters were
performed using ANOVA and multiple regression analyses. Data was presented as Mean6SD. In all statistical analyses p-
values ,0.05 were considered significant. Circulating chemerin levels were significantly higher in obese subjects with BMI
greater than 25 kg/m2 compared with those with a BMI below 25 kg/m2 (P = 0.001). Serum chemerin levels were found to
be independently and significantly associated with serum levels of cholesterol (P = 0.0160; r = 0.255), fasting glucose
(P = 0.002; r = 0.323), HOMA-IR (P = 0.004; r = 0.300) and hip circumference (P = 0.021; r = 0.246). This demonstrates that
chemerin levels are associated with obesity and dyslipidemia and may play a role in the development of insulin resistance.
This data suggests that chemerin may serve as an independent marker in diagnosing these conditions even before they
become clinically symptomatic.
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Introduction
Over the past few years, obesity has become a global epidemic
and has emerged as a major health problem associated with an
increased risk for cardiovascular disease, diabetes, dyslipidemia
and an increased mortality rate [1–3]. The popular argument is
that the epidemic is due to the changes in the societies’ so called
‘modernization’ leading to over nutrition and a sedentary lifestyle
[4].
According to the Asia Pacific Cohort Studies Collaboration [5],
the prevalence of obesity ranges from 0.6–4.0% in Asian Indians,
where genes, age and sex have been considered as non-modifiable
risk factors. A survey of Pakistan data [6] clearly demonstrated
that 1% of the Pakistani population was reported to be obese and
5% overweight in people aged 15–24 years of age. Similarly
Troiano et al. [7] and Jafer et al. [8] revealed that according to the
Asian specific body mass index (BMI) cutoff value of 23 kg/m2, 1
in 4 people in Pakistan over the age of 15 years are overweight or
obese.
The key element of obesity is white adipose tissue, which acts as
a multifunctional endocrine tissue, regulating adipocyte biology
and systemic processes like food intake, nutrient metabolism,
insulin sensitivity bone growth, inflammation and reproduction
[9], leading to an increased incidence of cardiovascular diseases
and Type 2 diabetes [10,11]. Obesity and physical inactivity are
two primary risk factors for the development of hypertension,
insulin resistance and dyslipidemia. Serum biomarkers have
emerged as important tools for prediction, diagnosis, and risk
stratification for patients with obesity related co morbidities
[12,13].
Chemerin, also known as Retinoic Acid Receptor Responder
Protein 2 (RARRES 2) is among the newly discovered adipokines.
Human pro-chemerin (the inactive form) is synthesized as 163
amino acids with a 20 amino acid hydrophobic signal peptide and
is activated through the cleavage of the C terminus by
inflammatory and coagulation serine proteases [14–16]. The
secreted, mature form of chemerin contains 146 amino acids, and
has a molecular weight of 16 kDa [16]. Due to its role in adipocyte
differentiation and glucose uptake, chemerin is classified as an
adipokine [17–20]. Chemerin was originally reported to be present
in circulation in plasma and serum respectively at 3 and 4.4 nM
concentrations in humans and 0.5 and 0. 6 nM concentration in
mice [21,22].
Chemerin has been recently described to be secreted from
mature adipocytes and the circulating levels of chemerin in human
plasma increased with obesity, which may suggest that chemerin
expression may reflect the state of differentiation of adipocytes,
adipocyte cell size or total body fat mass [17,23]. A critical
function of chemerin is to regulate adipogenesis and metabolic
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homeostasis in adipocytes and it may play an important role in
macrophage infiltration into adipose tissue [18].
Taken together chemerin is considered to be a marker of
adiposity and may have a key role in the development of health
consequences in obesity. We therefore hypothesized that circulat-
ing chemerin levels have an association with the degree of
corpulence. Consequently, this study aimed to examine the
relationship between chemerin and body fat percentage, serum
lipid, glucose, and insulin levels, in lean and obese healthy
volunteers.
Materials and Methods
We recruited 90 healthy male subjects, between ages 15–65
years, who visited the free body fat screening scheduled at the
Department of Physiology, Basic Medical Sciences Institute,
Jinnah Post Graduate Medical Centre, Karachi, Pakistan.
Ethics Statement
The research protocol was approved by the board of advanced
studies and research, University of Karachi (BASR No/9088/
BMSI) and the Basic Medical Sciences Institute research ethics
committee (14/2/11/SSF/BMSI). All clinical investigation was
conducted according to the principles expressed in the Declaration
of Helsinki. All the participants were volunteers who were
explained about the minimal risk research procedure and were
asked to complete a verbal and written informed consent.
All subjects included in the study had no previous history or
evidence of cardiovascular disease, diabetes, moderate to severe
hypertension (resting blood pressure (BP).170/100 mmHg),
dyslipidemia, body weight fluctuation of 5 kg in the recent 6
months, acute infectious disease or chronic inflammatory disease,
endocrine disease, cancer or medication usage that could affect
cardio metabolic function. Smokers, alcoholics and females were
excluded from our study.
The WHO Stepwise Approach to Surveillance (STEPS) [24]
protocol was used to measure the waist and hip circumference as
previously described. Waist to hip ratio was calculated by dividing
the waist circumference by hip circumference. BMI was calculated
by dividing weight by height squared (kg/m2) [25].
Blood samples were collected in the morning after an overnight
fast. Fasting glucose by GOD-PAP (Glucose Oxidase-Phenol-
Aminophenazone) method (Merck, France), total cholesterol by
Enzymatic Endpoint Method, triglyceride by GPO (Glycerol-3-
Phosphate Oxidase-Phenol Aminophenazone) method and HDL-
cholesterol levels by CHOD-PAP (Cholesterol Oxidase-Phenol
Aminophenazone) method (Randox Laboraties, UK), were
measured using a Spectrophotometer(model AE-350, Erma Inc.,
Tokyo, Japan). LDL-cholesterol levels were calculated using the
Friedewald equation [26].
Fasting insulin was measured using an ELISA kit (DIA source
Immuno Assay S.A., Belgium). Insulin resistance was calculated
using the homeostasis model assessment of insulin resistance
(HOMA-IR) index [fasting insulin (units per milliliter) x fasting
glucose milligram/deciliter)/405] [27]. The body fat percentage
was measured using Diagnostic Scale BG55 (Beurer Germany)
through bioelectrical impedance matching/analysis. Serum che-
merin levels were measured with an enzyme immunoassay kit
(Creative Diagnostics, USA), with a sensitivity of less than 3 pg/
ml, using ELISA plate reader equalizer ER 2005, (Eqiupar, Italy).
A descriptive statistical analysis of continuous variables was
performed using SPSS (version 11; SPSS Inc., Chicago, IL, USA).
Data on continuous variables i.e. biophysical (age, height, weight,
BMI, waist circumference, hip circumference, waist hip ratio,
body fat, blood pressure etc.) and biochemical (Serum cholesterol,
triglycerides, HDL, LDL, fasting blood glucose, fasting insulin and
serum chemerin etc.) parameters were calculated as mean 6
standard deviation (SD). Statistical comparisons were computed
using a student t-test and a one-way analysis of variance (ANOVA)
for continuous/quantitative variables, after adjusting for age, and
BMI. Pearson’s or Spearman’s coefficient of correlation (r) were
used to determine the correlation between serum chemerin levels
and lipid profile, fasting blood glucose, insulin and body fat
parameters wherever applicable. In all statistical analysis per-
formed p-values ,0.05 were considered significant.
Results
A total of 90 male subjects participated in this study and were
divided into three groups according to BMI criteria for South
Asian population [28]. Group A were subjects with normal weight
(BMI= 18–22.9 kg/m2), Group B were overweight (BMI=23–
25 kg/m2), Group C were obese (BMI.25 kg/m2) subjects. All
subjects were age matched and therefore no significant differences
were observed between the groups. The biochemical and
biophysical parameters of the subjects are outlined in Table 1
and Figure 1. Briefly, no significant changes were observed with
height among all groups, but weight portrayed a strong positive
correlation with serum chemerin concentrations (P,0.01;
r = 0.705). Serum chemerin concentration was significantly
increased in the obese group (Group C) (76.4613.4) as compared
to the normal weight group (Group A) (12.063.3) and overweight
group (Group B) (17.266.1) (P = 0.001; (Figure 2). This suggests
that the degree of adiposity determines the adipokine level, which
in turn may be responsible for metabolic disturbances found in
obesity.
Significant changes were observed in the diastolic blood
pressure in group B and C as compared to control A
(P= 0.001), and a significant positive correlation (P,0.01;
r = 0.302) was observed with serum chemerin concentration. Both
BMI (P= 0.001; r = 0.769) and total fat percentage (P = 0.001;
r = 0.550) were significantly associated with circulating chemerin
concentrations. Systolic blood pressure, pulse, temperature and
respiratory rate were non-significant in all groups.
Multiple regression analyses were used to assess the associations
between chemerin levels and biochemical parameters (Table 2).
Briefly, waist circumference (P= 0.001; r = 0.567) and hip
circumference (P= 0.001; r = 0.470) showed a positive correlation
with serum chemerin concentration, in group B and C as
compared to group A. Fasting plasma glucose levels (P = 0.001;
r = 0.531), serum insulin level (P = 0.001; r = 0.360), HOMA-IR
(P= 0.001; r = 0.524), showed positive correlations, while
QUICKI (P= 0.001; r =20.4), depicted negative correlations
with circulating chemerin concentration. Serum cholesterol
(P = 0.001; r = 0.575), serum triglyceride levels (P = 0.039;
r = 0.230) and LDL-C (P= 0.001; r = 0.487) were significantly
higher in group C subjects as compared to group B and A
(P= 0.001). While serum levels of HDL-C showed no significance
between any of the groups (P = 0.353; r =20.146), after adjust-
ment for age and BMI, cholesterol (P = 0.0160; r = 0.255), fasting
glucose (P= 0.002; r = 0.323), HOMA-IR (P= 0.004; r = 0.300),
and hip circumference (P= 0.021; r = 0.246) were found to be
independently associated with chemerin levels.
Discussion
Adipose tissue not only acts as an energy reservoir but also acts
like a remote endocrine organ and has an important role in
regulating energy homeostasis and metabolism by communicating
Chemerin Is Associated with Metabolic Syndrome
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with liver, skeletal muscle, and the brain [29,30]. Recently, the
new adipokine chemerin has been characterized to be associated
with increased white cell mass, and obesity induced inflammation
in adipose tissue [31,32]. Conde and his group [33] have identified
a novel role of chemerin stating that chemerin along with other
adipokines such as leptin, adiponectin, lipocalin and serum
amyloid A3 are also expressed in non-adipose tissues especially
the chondrocytes. This is plausible that these adipokines may then
regulate chondrocyte biology and bone development, apart from
their role in metabolic diseases. This may be reflected as altered
adipokine secretion which in turn promotes chronic inflammatory
state in rheumatic disease, including cartilage, synovium, bone and
various immune cells [34]. Chemerin, is a 16 kDa protein secreted
in an inactive form as prochemerin and is activated through the
cleavage of the C-terminus by inflammatory and coagulation
serine proteases [14]. In mice, chemerin mRNA is highly
expressed in white adipose tissue, liver and lung, and chemerin
knockdown impairs differentiation of adipocytes, reduces the
expression of GLUT4 while increasing expression of IL-6 and
insulin receptor and reduces lipolysis [17,18]. Furthermore, in
humans, plasma chemerin levels were significantly associated with
obesity parameters in several different populations [17,22,35–37].
Collectively, this suggests that chemerin may play a role in the
metabolic function of mature adipocytes.
Our results identified a significant increase in serum chemerin
levels in obese subjects, related to the amount of total percentage
of body fat. Chemerin prominently revealed a strong positive
correlation with increasing weight, BMI, waist and hip circum-
ference and body fat percentage, in a healthy population. This
data is consistent with previously published reports whereby gene
expressions as well as protein levels of chemerin and chemerin’s
receptor, CMKLR1 were significantly increased in mice fed a high
fat diet [17,37]. A marked increase in chemerin concentration was
also observed in obese individuals, linking with subcutaneous and
omental adipose tissue, BMI, WHR, and skinfold thickness [38–
40]. These studies are in agreement with the findings of our study.
We also established that the fasting glucose and insulin levels
were raised in obese subjects despite having no complaints or
symptoms of diabetes, these levels along with HOMA-IR showed a
strong positive correlation with chemerin, while QUICKI had a
negative correlation. Previous studies have shown significant
positive correlations between chemerin levels and fasting blood
Figure 1. Box-Plot of Anthropometric Parameters of Study Groups. (A) Body fat percentage (B) Hip circumference (C) Waist circumference
(D) Body mass index. Significant differences were observed in both overweight (Group B; p,0.05) and obese groups (Group C; p,0.01) compared
with normal weight group (Group A; p,0.05). There were 30 subjects per group.
doi:10.1371/journal.pone.0057113.g001
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glucose, fasting insulin, HOMA-IR, HbA1c, independent of age
and BMI were observed in subjects with type II diabetes compared
to normal glycemic subjects [39,41,42]. These studies are
consistent with our data, however it is important to note that
our data only incorporated and reported findings in healthy
subjects whereas other studies performed these associations in
diabetic humans and mice. Taken together, this may deduce a role
for chemerin as a screening tool in individuals who have higher
visceral fat accumulation contrasting to being in the range of
normal weight category, which is seen commonly in Asian
population. This is important, since BMI has some limitations as
a measure of adiposity across populations [43].
Fasting glucose levels and HOMA-IR remained independently
associated with chemerin levels even after adjustment for age and
BMI. Thus we can confidently conclude that chemerin levels may
affect glucose homeostasis and therefore may lead to the
development of insulin resistance [17]. These elevated serum
chemerin levels observed in human and mice suggest that
chemerin might also influence the dysregulation of glucose
metabolism that often occurs with obesity, via the induction of
insulin resistance especially in skeletal muscle. Recent studies
demonstrated that chemerin induces insulin resistance in skeletal
muscle by inhibiting insulin-stimulated Akt1 phosphorylation and
activating the 5 AMP-activated protein kinase (AMPK) [42],
glycogen synthase kinase 3 phosphorylation, and glucose uptake
[44].This decreased uptake could either be a result of down
regulation of glucose transporters or competitive inhibition of
chemerin to these receptors. Further studies are required to
evaluate these mechanisms.
Here, we demonstrated that in a healthy group of subjects,
serum cholesterol, triglyceride and LDL-C were significantly
higher in obese versus lean and overweight subjects, and that a
strong positive correlation of cholesterol, triglycerides and LDL-C
exists with chemerin, while serum levels of HDL-C showed non-
significant negative correlation with chemerin concentration.
These findings are comparable to various studies [38,45,46] with
a slight variation in our results being reported in healthy subjects
as opposed to diabetic subjects. Positive correlations between
triglycerides, HDL-C and systemic chemerin was also identified in
normal glycemic patients by Bozaoglu et al. [35] but no
correlations were observed by Becker et al. [42], Weigert et al.
[47] & Landgraf et al. [48]. These associations were lost after
adjusting data for age and BMI, but cholesterol levels showed a
positive correlation with chemerin even after that. These
observations suggest that chemerin could also be a regulator of
fat metabolism.
A strong positive correlation with diastolic blood pressure was
observed in this study. Comparable results were observed
suggesting that serum chemerin levels were significantly associated
with systolic hypertension even after adjusting for anthropometric
variables [17,41,48,49] however no correlation of blood pressure
with chemerin was identified by and Hah et al. [46]. We clearly
demonstrated that serum chemerin levels are associated with
parameters of metabolic syndrome including hypertension regard-
less of presence of other metabolic syndrome components,
signifying that chemerin may also be a distinctive regulator of
blood pressure because of its significant correlation with diastolic
pressure. Moreover, it has been shown that chemerin is
structurally similar to Bradykinin which is also involved in blood
pressure regulation [50].This effect of chemerin on blood pressure
may also relate to its high expression by kidneys, which is the
primary regulator of blood pressure [22,42].
Studies have reported that chemerin demonstrated no gender
dimorphism in a cohort of type II diabetic patients [47] in 55
healthy volunteers [22] & in non-obese chronic hepatitis patients
[51]. In contrast Tan et al. [38] and Bozaoglu et al. [17,23] found
that chemerin levels increased with age and that there appears to
be no diurnal variation in chemerin levels. However we found no
Figure 2. Box-Plot of Circulating Chemerin Levels. Elevated levels of chemerin were observed in obese males compared to normal weight and
overweight subjects.
doi:10.1371/journal.pone.0057113.g002
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significant association between chemerin levels and age, similar to
a study in a group of pregnant females [52]. While Landgraf et al.
[48] reported no correlation between sex and chemerin levels but
a negative relation with age and circulating levels especially in
boys. These differences may be due to the variations in culture and
environmental settings.
Chemerin may provide an exciting connection between obesity,
inflammation and obesity related pathophysiological changes in
humans. Even though a relationship of elevated serum levels in
obesity and metabolic syndrome has been suggested, further
studies are required that will provide valuable insight to verifying
the function of chemerin and determine whether excess chemerin
increases adiposity and deranges metabolic function or whether
elevated chemerin levels are a consequence or compensatory
response during and following the development of obesity and its
co morbidities which may lead to the potential therapeutic role of
chemerin to these prevalent disorders.
Conclusion
Obesity and physical inactivity are two primary risk factors for
the development of hypertension, insulin resistance and dyslipide-
mia. Significant associations between chemerin levels and various
phenotypes of the metabolic syndrome were observed in our
population. These findings suggest that chemerin may provide an
interesting screening or diagnostic tool for obesity and its
complications in humans and may represent a widespread
phenotypic relationship that is not population-specific. Whether
Table 1. Biophysical and Biochemical Characteristics of the study subjects.
Phenotypes Normal Weight Overweight Obese P value
Mean ± SD
n=30
Mean ± SD
n=30
Mean ± SD
n=30
Age (Year) 31.9615.0 33.369.4 38.6610.4 0.092
95% CI 26.88,38.06 29.79,36.88 34.75, 42.51 –
Weight (Kg) 57.967.10 71.267.11* 88.4616.2*,** 0.001
95% CI 55.28,60.60 68.46,73.76 82.35, 94.47 –
BMI 20.061.92 24.460.7* 31.964.6*,** 0.001
95% CI 19.32,20.76 24.10, 24.65 30.23, 33.65 –
Waist Circumference (cm) 77.4611.9 88.267.6* 100.4612.9*,** 0.001
95% CI 73.63,81.86 85.41, 91.11 95.59,105.22 –
Hip Circumference (cm) 88.0610.5 100.866.9* 109.3611.5*,** 0.001
95% CI 84.69,91.94 98.19,103.3 104.9,113.5 –
WHR 0.8860.11 0.8860.07 0.9160.07 0.247
95% CI 0.83, 0.92 0.85, 0.91 0.88, 0.94 –
Body Fat (%) 19.267.22 27.364.0* 34.964.5*,** 0.001
95% CI 16.89,21.89 25.75, 28.82 33.22, 36.56 –
Cholesterol (mg/dl) 144.4630.4 150.9639.0 209.1655.5*,** 0.001
95% CI 132.69,155.9 135.00,164.19 188.3,229.7 –
Triglycerides (mg/dl) 128.1646.7 142.0668.6 167.0656.0*,** 0.039
95% CI 110.6,145.57 116.26,167.53 146.12,187.9 –
HDL-C(mg/dl) 39.569.7 37.5768.6 36.466.4 0.353
95% CI 35.32, 42.60 34.51, 40.95 34.00,38.79 –
LDL-C (mg/dl) 74.1630.0 81.6640.7 134.8659.0*,** 0.001
95% CI 63.23, 85.61 66.32, 96.79 112.75,156.8 –
Fasting glucose (mg/dl) 83.6624.11 84.0618.5 126.9640.4*,** 0.001
95% CI 73.38,91.39 77.13, 90.99 111.83,142.02 –
Fasting Insulin (U/ml) 19.168.4 23.0610.0 35.4614.2*,** 0.001
95% CI 15.95, 22.21 19.24, 26.73 30.14, 40.74 –
HOMA-IR 4.163.2 4.962.8 11.066.0*,** 0.001
95% CI 2.85, 5.25 3.85, 5.99 8.80, 13.26 –
QIUCKI 0.3160.02 0.3160.03 0.2860.02*,** 0.001
95% CI 0.30, 0.32 0.29, 0.31 0.26, 0.28 –
Chemerin (pg/ml) 12.063.3 17.266.1 76.4613.4*,** 0.001
95% CI 10.69,13.14 14.93,19.54 56.49,96.39 –
WHR (waist hip ratio), QUICKI (Quantitative check index for insulin sensitivity), HOMA-IR (Homeostatic model of insulin resistance), BMI (Body mass index).
*Statistically significant as compared to control subjects, where p,0.05.
**Statistically significant as compared to overweight subjects, where p,0.01.
doi:10.1371/journal.pone.0057113.t001
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chemerin is a cause or consequence of these disorders remains to
be elucidated and requires further investigation.
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**Significant correlation whereby p,0.01.
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